Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)

WAYNE, Pa. — Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced QTORIN™ docetaxel, a new QTORIN™ program for the treatment of Extramammary Paget’s Disease (EMPD). QTORIN™ docetaxel is the Company’s third product candidate developed from QTORIN™, its proprietary platform for reproducibly generating novel, topical product candidates for the treatment of serious, rare skin diseases and vascular anomalies.

EMPD is a serious, rare, and life-threatening cancer that originates in the skin, most commonly on the vulva, scrotum, or perianal region. Patients live with red, scaly plaques that can itch, burn, weep, and ulcerate. EMPD can invade deeper tissue and progress to metastatic disease. Patients often undergo multiple disfiguring surgeries that require skin grafts, and EMPD has been documented to have high recurrence rates after treatment. There are no FDA-approved therapies for EMPD, which affects an estimated more than 10,000 patients in the U.S.

“Our objective is to bring meaningful innovation, and ultimately the first FDA-approved therapy, to the EMPD community,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “Today, patients with EMPD often face repeated, disfiguring surgeries and high rates of disease recurrence. QTORIN™ docetaxel builds on human clinical evidence of I.V. docetaxel in metastatic EMPD, with the potential to transform the treatment paradigm to first-line, localized topical therapy. EMPD has the hallmark characteristics of an opportunity where Palvella can make a significant impact: a serious, rare skin disease with no FDA-approved therapies, a compelling scientific rationale, and a clear path toward potentially delivering the first FDA-approved therapy.”

Palvella has initiated IND-enabling activities for QTORIN™ docetaxel, with plans to meet with the FDA in the first half of 2027 and subsequently initiate a Phase 2 study.

Webcast Conference Call Details

Palvella will host a conference call and live audiovisual webcast today at 8:30 a.m. ET to discuss its new program, QTORIN™ docetaxel. The call will be presentation-only. To access the live webcast with slides, please click here or visit the “Events & Presentations” section of the Company’s website at www.palvellatx.com. A replay will be available approximately two hours after the call and archived on the website for 90 days.

 

About Palvella Therapeutics

Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular anomalies for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular anomalies, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. Palvella’s third product candidate, QTORIN™ docetaxel, is currently being developed for the treatment of Extramammary Paget’s Disease. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).

QTORIN™ rapamycin, QTORIN™ pitavastatin, and QTORIN™ docetaxel are for investigational use only and have not been approved by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors

Wesley H. Kaupinen
Founder and CEO
Palvella Therapeutics
[email protected]

Media
Marcy Nanus
Vice President of Investor Relations and Corporate Affairs
Palvella Therapeutics
[email protected]